e10vq
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended September 30, 2006
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 000-21244
PAREXEL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its Charter)
|
|
|
Massachusetts
|
|
04-2776269 |
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification Number) |
|
|
|
200 West Street |
|
|
Waltham, Massachusetts
|
|
02451 |
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code (781) 487-9900
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or
a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule
12b-2 of the Exchange Act.
Large Accelerated Filer o Accelerated Filer þ Non-Accelerated Filer o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as of
the latest practicable date: As of November 5, 2006, there were 27,204,999 shares of common stock
outstanding.
PAREXEL INTERNATIONAL CORPORATION
INDEX
2
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PAREXEL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
|
|
|
|
2006 |
|
|
June 30, |
|
|
|
(Unaudited) |
|
|
2006 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
84,217 |
|
|
$ |
82,749 |
|
Marketable securities |
|
|
|
|
|
|
10,000 |
|
Billed and unbilled accounts receivable, net |
|
|
295,654 |
|
|
|
272,063 |
|
Prepaid expenses |
|
|
12,140 |
|
|
|
11,258 |
|
Deferred tax assets |
|
|
954 |
|
|
|
934 |
|
Other current assets |
|
|
6,541 |
|
|
|
8,074 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
399,506 |
|
|
|
385,078 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
80,690 |
|
|
|
78,386 |
|
Goodwill |
|
|
50,111 |
|
|
|
50,112 |
|
Other intangible assets, net |
|
|
7,527 |
|
|
|
7,832 |
|
Non-current deferred tax assets |
|
|
10,476 |
|
|
|
10,495 |
|
Other assets |
|
|
6,637 |
|
|
|
6,730 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
554,947 |
|
|
$ |
538,633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Notes payable and current portion of long-term debt |
|
$ |
5,494 |
|
|
$ |
498 |
|
Accounts payable |
|
|
8,364 |
|
|
|
17,185 |
|
Deferred revenue |
|
|
156,573 |
|
|
|
139,836 |
|
Accrued expenses |
|
|
15,737 |
|
|
|
20,117 |
|
Accrued restructuring charges |
|
|
5,728 |
|
|
|
5,190 |
|
Accrued employee benefits and withholdings |
|
|
39,940 |
|
|
|
46,385 |
|
Current deferred tax liabilities |
|
|
12,645 |
|
|
|
12,645 |
|
Income tax payable |
|
|
11,715 |
|
|
|
7,498 |
|
Other current liabilities |
|
|
2,740 |
|
|
|
4,172 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
258,936 |
|
|
|
253,526 |
|
Long-term debt, net of current portion |
|
|
628 |
|
|
|
705 |
|
Non-current deferred tax liabilities |
|
|
16,812 |
|
|
|
16,780 |
|
Long-term accrued restructuring charges |
|
|
8,394 |
|
|
|
10,967 |
|
Other liabilities |
|
|
7,751 |
|
|
|
5,569 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
292,521 |
|
|
|
287,547 |
|
|
|
|
|
|
|
|
Minority interest in subsidiary |
|
|
2,189 |
|
|
|
2,323 |
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred
stock$.01 par value; shares authorized: 5,000,000; Series A junior participating preferred
stock - 50,000 shares designated, none issued
and outstanding |
|
|
|
|
|
|
|
|
Common
stock$.01 par value; shares authorized: 50,000,000; shares
issued and outstanding: 27,191,636 at September 30, 2006 and 26,920,119
at June 30, 2006 |
|
|
286 |
|
|
|
283 |
|
Additional paid-in capital |
|
|
182,195 |
|
|
|
177,309 |
|
Retained earnings |
|
|
72,252 |
|
|
|
65,275 |
|
Accumulated other comprehensive income |
|
|
5,504 |
|
|
|
5,896 |
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
260,237 |
|
|
|
248,763 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
554,947 |
|
|
$ |
538,633 |
|
|
|
|
|
|
|
|
See notes to condensed consolidated financial statements.
3
PAREXEL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
|
|
2006 |
|
|
2005 |
|
Service revenue |
|
$ |
165,057 |
|
|
$ |
138,380 |
|
Reimbursement revenue |
|
|
38,450 |
|
|
|
31,188 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
203,507 |
|
|
|
169,568 |
|
|
|
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
|
|
|
Direct costs |
|
|
109,221 |
|
|
|
93,623 |
|
Reimbursable out-of-pocket expenses |
|
|
38,450 |
|
|
|
31,188 |
|
Selling, general and administrative |
|
|
38,039 |
|
|
|
34,051 |
|
Depreciation and amortization |
|
|
6,550 |
|
|
|
6,370 |
|
Restructuring benefit |
|
|
(74 |
) |
|
|
(679 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
192,186 |
|
|
|
164,553 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
|
11,321 |
|
|
|
5,015 |
|
|
Interest income |
|
|
2,457 |
|
|
|
1,894 |
|
Interest expense |
|
|
(1,761 |
) |
|
|
(1,416 |
) |
Other income (loss) |
|
|
(213 |
) |
|
|
559 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income |
|
|
483 |
|
|
|
1,037 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes
and minority interest expense (benefit) |
|
|
11,804 |
|
|
|
6,052 |
|
|
Provision for income taxes |
|
|
4,816 |
|
|
|
3,078 |
|
Minority interest expense (benefit), net of tax |
|
|
11 |
|
|
|
(344 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
6,977 |
|
|
$ |
3,318 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.26 |
|
|
$ |
0.13 |
|
Diluted |
|
$ |
0.25 |
|
|
$ |
0.13 |
|
|
|
|
|
|
|
|
|
|
Weighted average shares: |
|
|
|
|
|
|
|
|
Basic |
|
|
27,052 |
|
|
|
26,419 |
|
Diluted |
|
|
27,930 |
|
|
|
26,529 |
|
See notes to condensed consolidated financial statements.
4
PAREXEL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
|
|
2006 |
|
|
2005 |
|
Cash flow from operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
6,977 |
|
|
$ |
3,318 |
|
Adjustments to reconcile net income to net cash (used in) provided
by operating activities: |
|
|
|
|
|
|
|
|
Minority interest expense (benefit), net of tax |
|
|
11 |
|
|
|
(344 |
) |
Depreciation and amortization |
|
|
6,550 |
|
|
|
6,370 |
|
Stock-based compensation |
|
|
1,468 |
|
|
|
608 |
|
Changes in operating assets/liabilities |
|
|
(22,887 |
) |
|
|
(1,757 |
) |
|
|
|
|
|
|
|
Net cash (used in) provided by operating activities |
|
|
(7,881 |
) |
|
|
8,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from investing activities: |
|
|
|
|
|
|
|
|
Purchases of marketable securities |
|
|
(25,575 |
) |
|
|
|
|
Proceeds from sale of marketable securities |
|
|
35,575 |
|
|
|
4,000 |
|
Purchases of property and equipment |
|
|
(8,578 |
) |
|
|
(6,081 |
) |
Acquisition of businesses |
|
|
(39 |
) |
|
|
(5,479 |
) |
Proceeds from sale of assets |
|
|
71 |
|
|
|
6 |
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities |
|
|
1,454 |
|
|
|
(7,554 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
3,421 |
|
|
|
4,708 |
|
Payments to repurchase common stock |
|
|
|
|
|
|
(2,000 |
) |
Borrowings (repayments) under lines of credit and long-term
debt |
|
|
4,919 |
|
|
|
(26 |
) |
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
8,340 |
|
|
|
2,682 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(445 |
) |
|
|
28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
1,468 |
|
|
|
3,351 |
|
Cash and cash equivalents at beginning of period |
|
|
82,749 |
|
|
|
84,622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
84,217 |
|
|
$ |
87,973 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash
paid during the period for: |
|
|
|
|
|
|
|
|
Interest |
|
$ |
1,761 |
|
|
$ |
1,416 |
|
Income taxes, net of refunds |
|
$ |
203 |
|
|
$ |
4,193 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of assets acquired and goodwill |
|
$ |
39 |
|
|
$ |
6,274 |
|
Liabilities assumed |
|
|
|
|
|
|
(795 |
) |
|
|
|
|
|
|
|
Cash paid for acquisitions |
|
$ |
39 |
|
|
$ |
5,479 |
|
|
|
|
|
|
|
|
See notes to condensed consolidated financial statements.
5
PAREXEL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE
1 BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements of PAREXEL International
Corporation (PAREXEL or the Company) have been prepared in accordance with generally accepted
accounting principles for interim financial information and with the instructions of Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes
required by generally accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments (primarily consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included. Operating results for the three
months ended September 30, 2006 are not necessarily indicative of the results that may be expected
for other quarters or the entire fiscal year. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Companys Annual Report on Form 10-K for
the year ended June 30, 2006 (the 2006 10-K).
NOTE
2 EARNINGS PER SHARE
Basic earnings per share is computed by dividing net income for the period by the weighted average
number of common shares outstanding during the period. Diluted earnings per share is computed by
dividing net income by the weighted average number of common shares plus the dilutive effect of
outstanding stock options and shares issuable under the Companys employee stock purchase plan.
Outstanding options to purchase approximately 49,000 and 1.4 million shares of common stock were
excluded from the calculation of diluted earnings per share for the three months ended September
30, 2006 and 2005, respectively, because they were anti-dilutive.
The following table outlines the basic and diluted earnings per common share computations:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
($ in thousands, except per share data) |
|
2006 |
|
|
2005 |
|
Net income |
|
$ |
6,977 |
|
|
$ |
3,318 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding
used in computing basic earnings per share |
|
|
27,052 |
|
|
|
26,419 |
|
|
|
|
|
|
|
|
|
|
Dilutive common stock equivalents |
|
|
878 |
|
|
|
110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding
used in computing diluted earnings per share |
|
|
27,930 |
|
|
|
26,529 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share |
|
$ |
0.26 |
|
|
$ |
0.13 |
|
Diluted earnings per share |
|
$ |
0.25 |
|
|
$ |
0.13 |
|
NOTE 3 COMPREHENSIVE INCOME
Comprehensive income has been calculated by the Company in accordance with Financial
Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 130,
Reporting Comprehensive Income. Comprehensive income for the three months ended September 30,
2006 and 2005 was as follows:
6
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
($ in thousands) |
|
2006 |
|
|
2005 |
|
Net income |
|
$ |
6,977 |
|
|
$ |
3,318 |
|
Add: Foreign currency translation |
|
|
(313 |
) |
|
|
(1,177 |
) |
Unrealized gain (loss) on available for sale
securities and derivative instruments |
|
|
(79 |
) |
|
|
146 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income |
|
$ |
6,585 |
|
|
$ |
2,287 |
|
|
|
|
|
|
|
|
NOTE 4 STOCK-BASED COMPENSATION
Effective July 1, 2005, the Company adopted SFAS No. 123(R) Share-Based Payment under the
modified prospective method as described in SFAS No. 123(R). Under this transition method,
compensation expense recognized in the three months ended September 30, 2006 and 2005 includes
compensation expense for all stock-based payments granted during the quarter and for all
stock-based payments granted prior to, but not yet vested, as of July 1, 2005, based on the grant
date fair value estimated in accordance with the original provision of SFAS No. 123. For the three
months ended September 30, 2006, the amount of compensation expense recognized was $1.5 million, of
which $0.2 million was recorded in direct costs and $1.3 million was recorded in Selling, general
and administrative expense in the Condensed Consolidated Statement of Operations. For the three
months ended September 30, 2005, the amount of compensation expense recognized was $0.6 million, of
which $0.2 million was recorded in direct costs and $0.4 million was recorded in Selling, general
and administrative expense in the Condensed Consolidated Statement of Operations. The adoption of
SFAS No. 123(R) had no effect on cash flows for the three months ended September 30, 2006 and 2005.
There were no significant stock option and restricted stock grants during the three-month period
ended September 30, 2006.
NOTE 5 SEGMENT INFORMATION
The Company is managed through three business segments, namely, Clinical Research Services (CRS),
PAREXEL Consulting and MedCom Services (PCMS), and Perceptive Informatics, Inc. (Perceptive).
CRS constitutes the Companys core business and includes clinical trials management and
biostatistics, data management and clinical pharmacology, as well as related medical advisory and
investigator site services. PCMS provides technical expertise and advice in such areas as drug
development, regulatory affairs, and bio/pharmaceutical process and management consulting; and
provides a full spectrum of market development, product development, and targeted communications
services in support of product launch. PCMS consultants identify alternatives and propose
solutions to address clients product development, registration, and commercialization issues.
PCMS also provides health policy consulting and strategic reimbursement services. Perceptive
provides information technology solutions designed to improve clients product development
processes. Perceptive offers a portfolio of products and services that includes medical imaging
services, interactive voice response systems (IVRS), clinical trials management systems (CTMS),
web-based portals, systems integration, and patient diary applications.
The Company evaluates its segment performance and allocates resources based on service revenue and
gross profit (service revenue less direct costs), and allocates and evaluates other operating costs
on a geographic basis. Accordingly, the Company does not include selling, general, and
administrative expenses, depreciation and amortization expense, other income (expense), and income
tax expense in segment profitability. The Company attributes revenue to individual countries based
upon the number of hours of services performed in the respective countries and inter-segment
transactions are not included in service revenue. Furthermore, PAREXEL has a global infrastructure
supporting its business segments, and therefore, assets are not identified by reportable segment.
7
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
($ in thousands) |
|
2006 |
|
|
2005 |
|
Service revenue: |
|
|
|
|
|
|
|
|
Clinical Research Services |
|
$ |
120,236 |
|
|
$ |
99,348 |
|
PAREXEL Consulting and
MedCom Services |
|
|
29,310 |
|
|
|
26,745 |
|
Perceptive Informatics, Inc. |
|
|
15,511 |
|
|
|
12,287 |
|
|
|
|
|
|
|
|
|
|
$ |
165,057 |
|
|
$ |
138,380 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit on service revenue: |
|
|
|
|
|
|
|
|
Clinical Research Services |
|
$ |
41,079 |
|
|
$ |
32,226 |
|
PAREXEL Consulting and
MedCom Services |
|
|
8,637 |
|
|
|
7,979 |
|
Perceptive Informatics, Inc. |
|
|
6,120 |
|
|
|
4,552 |
|
|
|
|
|
|
|
|
|
|
|
$ |
55,836 |
|
|
$ |
44,757 |
|
|
|
|
|
|
|
|
NOTE 6 RESTRUCTURING CHARGES
During the three months ended September 30, 2006, the Company recorded a $0.1 million reduction to
the existing restructuring reserve as a result of changes in assumptions of leased facilities.
Current activity charged against the restructuring accrual in the three months ended September 30,
2006 (which is included in Current Liabilities Accrued Restructuring Charges and Long-term
Accrued Restructuring Charges in the Condensed Consolidated Balance Sheet) was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments/ |
|
|
|
|
|
|
Balance at |
|
|
|
|
|
|
Foreign |
|
|
Balance at |
|
|
|
June 30, |
|
|
Provision/ |
|
|
Currency |
|
|
September 30, |
|
($ in thousands) |
|
2006 |
|
|
Adjustments |
|
|
Exchange |
|
|
2006 |
|
Employee severance costs |
|
$ |
734 |
|
|
|
|
|
|
$ |
(251 |
) |
|
$ |
483 |
|
Facilities-related charges |
|
|
15,423 |
|
|
|
(74 |
) |
|
|
(1,710 |
) |
|
|
13,639 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
16,157 |
|
|
$ |
(74 |
) |
|
$ |
(1,961 |
) |
|
$ |
14,122 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOTE 7 STOCKHOLDERS EQUITY
On September 9, 2004, the Board of Directors approved a stock repurchase program authorizing
the purchase of up to $20.0 million of the Companys common stock to be repurchased in the open
market subject to market conditions. Unless terminated earlier by resolution of the Companys
Board of Directors, the Plan will expire when the entire amount authorized has been fully utilized.
Through September 30, 2006, the Company had acquired 620,414 shares at a total cost of $14.0
million under this program, leaving a remaining balance on the authorization of $6.0 million.
There were no additional shares repurchased during the first quarter
of fiscal year 2007 and the period from October 1, 2006 to November 7,
2006.
NOTE 8 RECENTLY ISSUED ACCOUNTING STANDARDS
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (FAS 157). FAS
157 provides guidance for using fair value to measure assets and liabilities. The standard also
responds to investors requests for more information about (1) the extent to which companies
measure assets and liabilities at fair value, (2) the information used to measure fair value, and
(3) the effect that fair-value measurements have on earnings. FAS 157 will apply whenever another
standard requires (or permits) assets or liabilities to be measured at fair value. The standard
does not expand the use of fair value to any new circumstances. FAS 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007, and interim periods within
those fiscal years and will be in effect for PAREXEL beginning on July 1, 2008. The Company is
currently evaluating the potential impact that the adoption of FAS 157 will have on its financial
statements.
8
In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income
Taxes (FIN 48). FIN 48 clarifies the accounting for uncertain income tax positions that are
recognized in a companys financial statements in accordance with the provisions of FASB Statement
No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax position taken or
expected to be taken in a tax return. FIN 48 also provides guidance on the derecognition of
uncertain positions, financial statement classification, accounting for interest and penalties,
accounting for interim periods and new disclosure requirements. FIN 48 is effective for fiscal
years beginning after December 15, 2006 and will be in effect for PAREXEL beginning on July 1,
2007. The Company is currently evaluating the potential impact that the adoption of FIN 48 will
have on its financial statements.
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections (FAS
154), which changes the requirements for the accounting and reporting of a change in accounting
principle. FAS 154 applies to all voluntary changes in accounting principle as well as to changes
required by an accounting pronouncement that does not include specific transition provisions. FAS
154 requires that changes in accounting principle be retrospectively applied. FAS 154 is effective
for accounting changes and corrections of errors made in fiscal years beginning after December 15,
2005. PAREXEL adopted FAS 154 on July 1, 2006 and the adoption of this statement did not have a
material impact on the Companys financial statements in the
first quarter of fiscal year 2007.
NOTE 9 INCOME TAXES
For the three months ended September 30, 2006 and 2005, the Company had an effective income tax
rate of 40.8% and 50.9%, respectively. The favorable movement in the tax rate was primarily
attributable to projected profitability improvements in the United States (U.S.). The Company has
evaluated the likelihood of unfavorable adjustments arising from on-going reviews by taxing
authorities and believes adequate provisions have been made in the income tax provision.
NOTE
10 COMMITMENTS, CONTINGENCIES AND GUARANTEES
In
connection with the Integrated Marketing Concepts (IMC)
acquisition during fiscal year 2005, as discussed in Note 3 to the
Consolidated Financial Statements included in Item 8 of the
Companys 2006 10-K, the Company agreed to make additional
payments of up to $2.9 million in contingent purchase price if IMC
achieves certain established financial targets through March 31,
2008. As of September 30, 2006, the Company had paid $0.6 million in
earn-out payments under the terms of the IMC acquisition.
In
connection with the Qdot acquisition, as discussed in Note 3 to the
Consolidated Financial Statements included in Item 8 of the
Companys 2006 10-K, the Company agreed to make maximum
additional payments of approximately $3.0 million in contingent
purchase price if Qdot achieves certain established financial targets
through June 30, 2008. As of September 30, 2006, the Company had
paid approximately $0.8 million in contingent earn-out payments.
The
Company has letter-of-credit agreements with banks totaling
approximately $5.7 million guaranteeing performance under various
operating leases and vendor agreements. In addition, the
Companys $15.0 million line of credit with JP Morgan Chase
Bank, N.A. is guaranteed by some of PAREXELs U.S. entities.
As of
September 30, 2006, the Company had approximately $3.9 million in
purchase obligations with various vendors for the purchase of
computer software and recruiting services.
NOTE
11 SUBSEQUENT EVENTS
On October 12, 2006, PAREXEL entered into a definitive purchase agreement to acquire the
business and operations of California Clinical Trials Medical Group, Inc. (CCT) and Behavioral
and Medical Research, LLC (BMR). Established in 1981 with headquarters in San Diego, CCT and BMR
provide a broad range of specialty Phase I IV clinical research services through four clinical
sites in California. The purchase price is $65 million, and the acquisition is expected to close
during the second quarter of fiscal year 2007. The Company plans to finance the acquisition with
borrowings under new financing arrangements and existing cash.
Subsequent to the quarter ended September 30, 2006, the Company received notice that a
clinical trials contract in the $50 million range is highly likely to be cancelled, unrelated to
PAREXELs performance on the project. The contract will likely be removed from backlog in the
second quarter of this fiscal year.
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The financial information discussed below is derived from the Condensed Consolidated Financial
Statements included herein. The financial information set forth and discussed below is unaudited
but, in the opinion of management, reflects all adjustments (primarily consisting of normal
recurring adjustments) considered necessary for a fair presentation of such information. The
Companys results of operations for a particular quarter may not be indicative of results expected
during subsequent fiscal quarters or for the entire year.
This quarterly report on Form 10-Q includes forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. For this purpose, any statements contained in this report regarding the
Companys strategy, future operations, financial position, future revenue, projected costs,
prospects, plans and objectives of management, other than statements of historical facts, are
forward-looking statements. The words anticipates, believes, estimates, expects,
intends, may, plans, projects, will, would, targets, and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. The Company cannot guarantee that they actually will achieve the
plans, intentions or expectations expressed or implied in its forward-looking statements. There
are a number of important factors that could cause actual results, levels of activity, performance
or events to differ materially from those expressed or implied in the forward-looking statements
the Company makes. These important factors are described under Critical Accounting Policies and
Estimates and under Risk Factors set forth in Item
1A below. Although the Company may elect to update
forward-looking statements in the future, it specifically disclaims any obligation to do so, even
if its estimates change, and readers
9
should not rely on those forward-looking statements as representing the Companys views as of any
date subsequent to the date of this quarterly report.
OVERVIEW
The Company is a leading bio/pharmaceutical services company, providing a broad range of
expertise in clinical research, medical marketing, consulting and informatics and advanced
technology products and services to the worldwide pharmaceutical, biotechnology, and medical device
industries. The Companys primary objective is to provide solutions for managing the
bio/pharmaceutical product lifecycle with the goal of reducing the time, risk and cost associated
with the development and commercialization of new therapies. Since its founding in 1983, PAREXEL
has developed significant expertise in processes and technologies supporting this strategy. The
Companys product and service offerings include: clinical trials management, data management,
biostatistical analysis, medical marketing, clinical pharmacology, patient recruitment, regulatory
and product development consulting, health policy and reimbursement, performance improvement,
industry training and publishing, medical imaging services, IVRS, CTMS, web-based portals, systems
integration, patient diary applications, and other drug development consulting services. The
Company believes that its comprehensive services, depth of therapeutic area expertise, global
footprint and related access to patients, and sophisticated information technology, and experience
in global drug development and product launch services represent key competitive strengths.
The Company is managed through three business segments, namely, CRS, PCMS and Perceptive.
|
|
|
CRS constitutes the Companys core business and includes clinical trials management
and biostatistics, data management and clinical pharmacology, as well as related medical
advisory and investigator site services. |
|
|
|
|
PCMS provides technical expertise and advice in such areas as drug development,
regulatory affairs, and bio/pharmaceutical process and management consulting; and
provides a full spectrum of market development, product development, and targeted
communications services in support of product launch. PCMS consultants identify
alternatives and propose solutions to address clients product development, registration,
and commercialization issues. PCMS also provides health policy consulting and strategic
reimbursement services. |
|
|
|
|
Perceptive provides information technology solutions designed to improve clients
product development processes. Perceptive offers a portfolio of products and services
that includes medical imaging services, IVRS, CTMS, web-based portals, systems
integration, and patient diary applications. |
The Company conducts a significant portion of its operations in foreign countries. Approximately
64.2% of the Companys consolidated service revenue for the three months ended September 30, 2006
and 63.5% of the Companys consolidated service revenue for the three months ended September 30,
2005, were from non-U.S. operations. Because the Companys financial statements are denominated in
U.S. dollars, changes in foreign currency exchange rates can have a significant effect on its
operating results. For the three months ended September 30, 2006, 16.0% of total consolidated
service revenue was denominated in British pounds and approximately 36.3% of total consolidated
service revenue was denominated in Euros. For the three months ended September 30, 2005, 18.4% of
total consolidated service revenue was denominated in British pounds and approximately 35.5% of
total consolidated service revenue was denominated in Euros.
Approximately 90% of the Companys contracts are fixed rate, with some variable components, and
range in duration from a few months to several years. Cash flows from these contracts typically
consist of a down payment required to be paid at the time of contract execution with the balance
due in installments over the contracts duration, usually on a milestone achievement basis.
Revenue from these contracts is generally recognized as work is performed. As a result, cash
receipts do not necessarily correspond to costs incurred and revenue recognized on contracts.
Generally, the Companys clients can terminate their contracts with the Company upon thirty to
sixty days notice or can delay execution of services. Clients may terminate or delay contracts for
a variety of reasons, including: merger or potential merger-related activities involving the
client, the failure of products being tested to satisfy safety requirements or efficacy criteria,
unexpected or undesired clinical results of the product, client cost reductions as a result of
budgetary limits or changing priorities, the clients decision to forego a particular study,
insufficient patient enrollment or investigator recruitment, or clinical drug manufacturing
problems resulting in shortages of the product.
10
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of the Companys financial condition and results of operations are
based on the Companys consolidated financial statements, which have been prepared in accordance
with accounting principles generally accepted in the U.S. The preparation of these financial
statements requires the Company to make estimates and assumptions that affect the reported amounts
of assets and liabilities, revenues and expenses, and other financial information. On an ongoing
basis, the Company evaluates its estimates and judgments. The Company bases its estimates on
historical experience and on various other factors that it believes to be reasonable under the
circumstances. Actual results may differ from these estimates under different assumptions or
conditions.
The Company regards an accounting estimate underlying its financial statements as a critical
accounting estimate if the nature of the estimate or assumption is material due to level of
subjectivity and judgment involved or the susceptibility of such matter to change and if the impact
of the estimate or assumption on financial condition or operating performance is material. The
Company believes that the following accounting policies are most critical to aid in fully
understanding and evaluating its reported financial results:
REVENUE RECOGNITION
Service revenue on fixed-price contracts is recognized as services are performed. The Company
measures progress for fixed-price contracts using the concept of proportional performance based
upon a unit-based output method. Changes in the scope of work generally result in a renegotiation
of contract pricing terms. Renegotiated amounts are not included in net revenues until earned and
realization is assured. Costs are not deferred in anticipation of contracts being awarded, but
instead are expensed as incurred. Historically, there have not been any significant variations
between contract estimates and the actual cost incurred that were not recovered from clients.
BILLED ACCOUNTS RECEIVABLE, UNBILLED ACCOUNTS RECEIVABLE AND DEFERRED REVENUE
Billed accounts receivable represent amounts for which invoices have been sent to clients.
Unbilled accounts receivable represent amounts recognized as revenue for which invoices have not
yet been sent to clients. Deferred revenue represents amounts billed or payments received for
which revenue has not yet been earned. The Company maintains a provision for losses on receivables
based on historical collectability and specific identification of potential problem accounts. In
the event the Company is unable to collect portions of its outstanding billed or unbilled
receivables, there may be a material impact to the Companys consolidated results of operations and
financial position.
INCOME TAXES
The Companys global provision for corporate income taxes is determined in accordance with
Statement of Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes, which
requires that deferred tax assets and liabilities be recognized for the effect of temporary
differences between the book and tax basis of recorded assets and liabilities. A valuation
allowance is established if it is more likely than not that future tax benefits from the deferred
tax assets will not be realized. Income tax expense is based on the distribution of profit before
tax among the various taxing jurisdictions in which the Company operates, adjusted as required by
the tax laws of each taxing jurisdiction. Changes in the distribution of profits and losses among
taxing jurisdictions may have a significant impact on the Companys effective tax rate.
Interim tax provision calculations are prepared during the year based on estimates. Differences
between these interim estimates and the final results for the year could materially impact the
Companys effective tax rate and its consolidated results of operations and financial position.
The Company is required under Financial Interpretation No. 18, Accounting for Income Taxes in
Interim Periods an Interpretation of APB Opinion No. 28 to exclude from its quarterly worldwide
effective income tax rate calculation losses in jurisdictions where no tax benefit can be
recognized. As a result, the Companys effective tax rate may fluctuate significantly on a
quarterly basis.
The amount of income taxes the Company pays is subject to ongoing audits by federal, state and
foreign tax authorities, which may result in proposed assessments. The Companys estimate for the
potential outcome for any uncertain tax issue is based on judgment. The Company believes it has
adequately provided for any reasonably foreseeable outcome related to these matters. However,
future results may include favorable or unfavorable adjustments to the Companys estimated tax
liabilities in the period assessments are made or resolved or when statutes of limitation on
potential assessments expire.
11
GOODWILL
Goodwill represents the excess of the cost of an acquired business over the fair value of the
related net assets at the date of acquisition. Under SFAS No. 142, Goodwill and Other Intangible
Assets, goodwill is subject to annual impairment testing or more frequent testing if an event
occurs or circumstances change that would more likely than not reduce the carrying value of the
reporting unit below its fair value. The Company has assessed the impairment of goodwill under
SFAS No. 142 in fiscal years 2006 and 2005. The impairment testing involves determining the fair
market value of each of the reporting units with which the goodwill was associated and comparing
that value with the reporting units carrying value. Based on this assessment, there was no
impairment identified at June 30, 2006 or 2005. Any future impairment of goodwill could have a
material impact to the Companys financial position or its results of operations.
RESULTS OF OPERATIONS
ANALYSIS BY SEGMENT
The Company evaluates its segment performance and allocates resources based on service revenue and
gross profit (service revenue less direct costs), while other operating costs are allocated and
evaluated on a geographic basis. Accordingly, the Company does not include the impact of selling,
general, and administrative expenses, depreciation and amortization expense, other income
(expense), and income tax expense in segment profitability. The Company attributes revenue to
individual countries based upon the number of hours of services performed in the respective
countries and inter-segment transactions are not included in service revenue. Furthermore, PAREXEL
has a global infrastructure supporting its business segments and therefore, assets are not
identified by reportable segment. Service revenue, direct costs and gross profit on service
revenue for the three months ended September 30, 2006 and 2005 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended September 30, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase |
|
|
|
|
($ in thousands) |
|
2006 |
|
|
2005 |
|
|
(Decrease) |
|
|
% |
|
Service revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRS |
|
$ |
120,236 |
|
|
$ |
99,348 |
|
|
$ |
20,888 |
|
|
|
21.0 |
% |
PCMS |
|
|
29,310 |
|
|
|
26,745 |
|
|
|
2,565 |
|
|
|
9.6 |
% |
Perceptive |
|
|
15,511 |
|
|
|
12,287 |
|
|
|
3,224 |
|
|
|
26.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
165,057 |
|
|
$ |
138,380 |
|
|
$ |
26,677 |
|
|
|
19.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRS |
|
$ |
79,157 |
|
|
$ |
67,122 |
|
|
$ |
12,035 |
|
|
|
17.9 |
% |
PCMS |
|
|
20,673 |
|
|
|
18,766 |
|
|
|
1,907 |
|
|
|
10.2 |
% |
Perceptive |
|
|
9,391 |
|
|
|
7,735 |
|
|
|
1,656 |
|
|
|
21.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
109,221 |
|
|
$ |
93,623 |
|
|
$ |
15,598 |
|
|
|
16.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit on
service revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRS |
|
$ |
41,079 |
|
|
$ |
32,226 |
|
|
$ |
8,853 |
|
|
|
27.5 |
% |
PCMS |
|
|
8,637 |
|
|
|
7,979 |
|
|
|
658 |
|
|
|
8.2 |
% |
Perceptive |
|
|
6,120 |
|
|
|
4,552 |
|
|
|
1,568 |
|
|
|
34.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
55,836 |
|
|
$ |
44,757 |
|
|
$ |
11,079 |
|
|
|
24.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THREE MONTHS ENDED SEPTEMBER 30, 2006 COMPARED WITH THREE MONTHS ENDED SEPTEMBER 30, 2005:
Service revenue increased $26.7 million, or 19.3%, to $165.1 million for the three months ended
September 30, 2006 from $138.4 million for the three months ended September 30, 2005. On a
geographic basis, service revenue for the three months ended September 30, 2006 was distributed as
follows: United States $59.0 million (35.8%), Europe $94.2 million (57.0%), and Asia & Other -
$11.9 million (7.2%). For the three months ended September
30, 2005, service revenue was distributed as follows: United States $50.4 million (36.5 %),
Europe $80.7 million (58.3 %), and Asia & Other $7.3 million (5.2 %).
12
On a segment basis, CRS service revenue increased by $20.9 million, or 21.0%, to $120.2 million in
the three months ended September 30, 2006 from $99.3 million in the three months ended September
30, 2005. Of the total $20.9 million increase, $19.5 million was attributed to business growth
across all CRS business units, with the remaining $1.9 million attributed to foreign currency
fluctuations. PCMS service revenue increased by $2.6 million, or 9.6%, to $29.3 million in the
three months ended September 30, 2006 from $26.7 million in the three months ended September 30,
2005. Of the total $2.6 million increase, $3.3 million was attributed to a strong performance in
the consulting business, which was offset by a $0.7 million decline caused by weakness in the
MedCom business. Perceptive service revenue increased by $3.2 million, or 26.2%, to $15.5 million
for the three months ended September 30, 2006 from $12.3 million in the three months ended
September 30, 2005. The year-over-year increase was mainly the result of strong growth in the
Companys medical imaging, integration services and IVRS.
Reimbursement revenue consists of reimbursable out-of-pocket expenses incurred on behalf of and
reimbursable by clients. Reimbursement revenue does not yield any gross profit to the Company, nor
does it have an impact on net income.
Direct costs increased by $15.6 million, or 16.7%, to $109.2 million for the three months ended
September 30, 2006 from $93.6 million in the three months ended September 30, 2005. On a segment
basis, CRS direct costs increased by $12.0 million, or 17.9%, to $79.1 million for the three months
ended September 30, 2006 from $67.1 million in the three months ended September 30, 2005. The
year-over-year increase in CRS direct costs was primarily due to higher labor and related costs
incurred to support higher revenue levels. As a percentage of service revenue, CRS direct costs
decreased by 1.8 points to 65.8% for the three months ended September 30, 2006 from 67.6% for the
three months ended September 30, 2005 primarily due to improved productivity and better performance
in the U.S. PCMS direct costs increased by $1.9 million, or 10.2%, to $20.7 million in the three
months ended September 30, 2006 from $18.8 million in the three months ended September 30, 2005.
The year-over-year increase in PCMS direct costs was primarily due to higher labor costs associated
with higher revenue levels. As a percentage of service revenue, PCMS direct costs remained
relatively flat at 70.5% for the three months ended September 30, 2006 and 70.2% for the three
months ended September 30, 2005. Perceptive direct costs increased $1.7 million, or 21.4%, to $9.4
million in the three months ended September 30, 2006 from $7.7 million in the three months ended
September 30, 2005. The year-over-year increase in Perceptive direct costs is primarily due to
higher labor costs associated with increased staffing needs to support business growth. As a
percentage of service revenue, Perceptives direct costs decreased by 2.5 points to 60.5% in the
three months ended September 30, 2006 from 63.0% in the three months ended September 30, 2005
primarily because there was no counterpart in recording compensation expense in conjunction with
the buyback of the minority interest in Perceptive in the first quarter of fiscal year 2006.
Selling, general and administrative (SG&A) expenses increased by $4.0 million, or 11.7%, to $38.0
million in the three-month period ended September 30, 2006 from $34.0 million in the three months
ended September 30, 2005. Of the total $4.0 million increase, $1.1 million was attributed to
increased spending for research and development, $1.0 million in higher selling and promotion
costs, $0.9 million was related to higher stock-based compensation; approximately $0.6 million was
caused by foreign exchange fluctuation, with the remaining $0.4 million related to other sources.
As a percentage of service revenue, SG&A decreased by 1.6 points to 23.0% in the three months ended
September 30, 2006 from 24.6% in the three months ended September 30, 2005 mainly because of
substantial leverage associated with strong revenue growth and the lack of a counterpart to
recording compensation expense in conjunction with the buyback of the minority interest in
Perceptive in the prior year period.
Depreciation and amortization (D&A) expense was $6.6 and $6.4 million for the three months
ended September 30, 2006 and 2005, respectively. As a percentage of service revenue, D&A decreased
by 0.6 points to 4.0% in the three months ended September 30, 2006 from 4.6% in the three months
ended September 30, 2005.
During the three months ended September 30, 2006, the Company recorded a $0.1 million reduction to
the existing restructuring reserve as a result of changes in assumptions related to facilities
sub-leases. During the three months ended September 30, 2005, the Company recorded a $1.2 million
reduction to the existing restructuring reserve as a result of changes in assumptions primarily
related to facilities sub-leases, which was partially offset by $0.5 million in severance-related
restructuring activity.
Other income decreased by $0.5 million, or 53.4% to $0.5 million in the three months ended
September 30, 2006 from $1.0 million in the three months ended September 30, 2005. The change was
due to a swing in foreign exchange from a gain to a loss.
13
The Company had an effective income tax rate of 40.8% for the three months ended September 30,
2006 and 50.9% for the three months ended September 30, 2005. The favorable movement in the tax
rate was primarily attributable to projected profitability improvements in the U.S. The Company has
evaluated the likelihood of unfavorable adjustments arising from on-going reviews by taxing
authorities and believes adequate provisions have been made in the income tax provision.
LIQUIDITY AND CAPITAL RESOURCES
Since its inception, the Company has financed its operations and growth, including
acquisitions, with cash flow from operations and proceeds from the sale of equity securities.
Investing activities primarily reflect acquisition costs and capital expenditures for information
systems enhancements and leasehold improvements.
Approximately 90% of the Companys contracts are fixed rate, with some variable components, and
range in duration from a few months to several years. Cash flows from these contracts typically
consist of a down payment required to be paid at the time of contract execution with the balance
due in installments over the contracts duration, usually on a milestone achievement basis.
Revenue from these contracts is generally recognized as work is performed. As a result, cash
receipts do not necessarily correspond to costs incurred and revenue recognized on contracts.
Generally, the Companys clients can terminate their contracts with the Company upon thirty to
sixty days notice or can delay execution of services. Clients may terminate or delay contracts for
a variety of reasons, including: merger or potential merger-related activities involving the
client, the failure of products being tested to satisfy safety requirements or efficacy criteria,
unexpected or undesired clinical results of the product, client cost reductions as a result of
budgetary limits or changing priorities, the clients decision to forego a particular study,
insufficient patient enrollment or investigator recruitment, or clinical drug manufacturing
problems resulting in shortages of the product.
DAYS SALES OUTSTANDING
The Companys operating cash flow is heavily influenced by changes in the levels of billed and
unbilled receivables and deferred revenue. These account balances as well as days sales
outstanding (DSO) in accounts receivable, net of deferred revenue, can vary based on contractual
milestones and the timing and size of cash receipts. DSO was 55 days at September 30, 2006, 49 days
at June 30, 2006, and 42 days at September 30, 2005. The increase in DSO was caused by record
levels of billing in August and September 2006 as a result of triggering an unusually high level of
billing milestones. Accounts receivable, net of the provision for losses on receivables was $295.7
million ($173.1 million in billed accounts receivable and $122.6 million in unbilled accounts
receivable) at September 30, 2006 and $272.1 million ($152.2 million in billed accounts receivable
and $119.9 million in unbilled accounts receivable) at June 30, 2006. Deferred revenue was $156.6
million at September 30, 2006 and $139.8 million at June 30, 2006. DSO is calculated by adding the
end-of-period balances for billed and unbilled account receivables, net of deferred revenue and the
provision for losses on receivables, then dividing the resulting amount by the sum of total revenue
plus investigator fees billed for the most recent quarter, and multiplying the resulting fraction
by the number of days in the quarter.
CASH FLOWS
Net cash used in operating activities for the three months ended September 30, 2006 totaled $7.9
million and was attributable to an $8.8 million decrease in accounts payable, a $7.9 million
decrease in other current and non-current liabilities, and a $6.9 million increase in account
receivable (net of allowance for doubtful accounts and deferred revenue), offset by 7.0 million of
net income, $6.5 million related to non-cash charges for depreciation and amortization expense,
$1.5 million in stock-based compensation expense, and a $0.7 million decrease in prepaid expenses
and other assets. Net cash provided by operating activities for the three months ended September
30, 2005 totaled $8.2 million and consisted of $6.4 million related to non-cash charges for
depreciation and amortization expense, $3.3 million of net income, a $1.5 million decrease in
accounts receivable (net of allowance for doubtful accounts and deferred revenue), and a $1.1
million increase in other current and non-current liabilities, offset by a $3.4 million decrease in
accounts payable, a $0.4 million increase in prepaids and other assets, and a $0.3 million decrease
in other sources.
14
Net cash provided by investing activities for the three months ended September 30, 2006 totaled
$1.5 million and consisted of $10.0 million of net proceeds from the sales of marketable securities
and $0.1 million from other sources, offset by $8.6 million used for capital expenditures
(primarily analytical equipment and computer software and hardware). Net cash used in investing
activities for the three months ended September 30, 2005 totaled $7.6 million and consisted of $6.1
million of capital expenditures (primarily analytical equipment and computer software and
hardware), $5.5 million for the acquisition of Qdot and the acquisition of the equity interest of
minority stockholders in Perceptive, offset by $4.0 million in proceeds from the sale of marketable
securities.
Net cash provided by financing activities for the three months ended September 30, 2006 totaled
$8.3 million, and consisted of $5.0 million in borrowing under a line of credit and $3.4 million
from proceeds related to the issuance of common stock in conjunction with the Companys stock
option plan, offset by $0.1 million used for payment of capital lease obligations. Net cash
provided by financing activities for the three months ended September 30, 2005 totaled $2.7
million, and consisted of $4.7 million in proceeds related to the issuance of common stock in
conjunction with the Companys stock option plan, offset by $2.0 million used to repurchase the
Companys common stock pursuant to its stock repurchase program.
LINES OF CREDIT
The Company has a line of credit with ABN AMRO Bank, NV in the amount of Euro 12.0 million. This
line of credit is not collateralized, is payable on demand, and bears interest at a rate ranging
between 4% and 6%. The line of credit may be revoked or canceled by the bank at any time at its
discretion. The Company primarily entered into this line of credit to facilitate business
transactions with the bank. At September 30, 2006, the Company had approximately Euro 12.0 million
available under this line of credit.
The Company has other foreign lines of credit with banks totaling approximately $1.8 million.
These lines of credit are used as overdraft protection and bear interest at rates ranging from 5%
to 7%. The lines of credit are payable on demand and are supported by PAREXEL International
Corporation. At September 30, 2006, the Company had approximately $1.8 million available under
these arrangements.
The Company has a cash pooling arrangement with ABN AMRO Bank. Pooling occurs when debit balances
are offset against credit balances and the net position is used as a basis by the bank for
calculating interest. Each legal entity owned by the Company and party to this arrangement remains
the owner of either a credit or debit balance. Therefore, interest income is earned in legal
entities with credit balances, while interest expense is charged to legal entities with debit
balances. Based on the pools overall balance, the Bank then (1) recalculates the overall interest
to be charged or earned, (2) compares this amount with the sum of previously charged/earned
interest amounts per account and (3) additionally pays/charges the difference. Interest income and
interest expense are included in other income (expense), net in the Companys Condensed
Consolidated Statements of Operations.
To fund its U.S. operations, the Company has in place an unsecured, uncommitted line of credit with
JP Morgan Chase Bank, N.A. for up to USD $15.0 million. The line bears interest rates based on
either Libor or Prime rates, as the Company selects. PAREXEL borrowed
$5.0 million under this line of credit during the first quarter of
fiscal year 2007. As of September 30, 2006, the amount
outstanding under this line was $5.0 million. On October 2, 2006 this $5.0 million was repaid in
full.
FINANCING NEEDS
The Companys primary cash needs are for the payment of salaries and fringe benefits, hiring and
recruiting expenses, business development costs, acquisition-related costs, capital expenditures,
and facility-related expenses. The Companys principal source of cash is from contracts with
clients. If the Company were unable to generate new contracts with existing and new clients or if
the level of contract cancellations increased, the Companys revenue and cash flow would be
adversely affected (see Item 1ARisk Factors for further detail). Absent a material adverse change in
the level of the Companys new business bookings or contract cancellations, PAREXEL believes that
its existing capital resources together with cash flow from operations and borrowing capacity under
existing lines of credit will be sufficient to meet its foreseeable cash needs over the next twelve
months and on a longer term basis.
In the future, the Company expects to continue to acquire businesses to enhance its service and
product offerings, expand its therapeutic expertise, and/or increase its global presence. Any such
acquisitions may require additional external financing, and the Company may from time to time seek
to obtain funds from public or private issuances of equity or debt securities. The Company may be
unable to secure such financing on terms acceptable to the Company.
15
The Company expects capital expenditures to total approximately $32.0 million in fiscal year
2007. As of September 30, 2006, the Company had spent approximately $8.6 million and expects to
spend an additional $23.4 million primarily for computer software and hardware, analytical
equipment, and leasehold improvements during the remainder of the fiscal year.
On September 9, 2004, the Board of Directors approved a stock repurchase program authorizing
the purchase of up to $20.0 million of the Companys common stock to be repurchased in the open
market subject to market conditions. As of September 30, 2006, the Company had acquired 620,414
shares at a total cost of $14.0 million under this program. There were no repurchases made during
the three months ended September 30, 2006.
As
discussed in Note 11 to the Condensed Consolidated Financial Statements included in Item 1 of
this quarterly report, on October 12, 2006, PAREXEL entered into a definitive purchase agreement to
acquire the business and operations of CCT and BMR. Established in 1981 with headquarters in San
Diego, CCT and BMR provide a broad range of specialty Phase I IV clinical research services
through four clinical sites in California. The purchase price is $65 million, and the acquisition
is expected to close during the second quarter of fiscal year 2007. The Company plans to finance
the acquisition with borrowings under new financing arrangements and existing cash.
COMMITMENTS, CONTINGENCIES AND GUARANTEES
In connection with the Integrated Marketing Concepts (IMC) acquisition during fiscal year 2005,
as discussed in Note 3 to the Consolidated Financial Statements included in Item 8 of the Companys
2006 10-K, the Company agreed to make additional payments of up to $2.9 million in contingent
purchase price if IMC achieves certain established financial targets through March 31, 2008. As of
September 30, 2006, the Company had paid $0.6 million in earn-out payments under the terms of the
IMC acquisition.
In connection with the Qdot acquisition, as discussed in Note 3 to the Consolidated Financial
Statements included in Item 8 of the Companys 2006 10-K, the Company agreed to make maximum
additional payments of approximately $3.0 million in contingent purchase price if Qdot achieves
certain established financial targets through June 30, 2008. As of September 30, 2006, the Company
had paid approximately $0.8 million in contingent earn-out payments.
The Company has letter-of-credit agreements with banks totaling approximately $5.7 million
guaranteeing performance under various operating leases and vendor
agreements. In addition, the Companys $15.0 million line of
credit with JP Morgan Chase Bank, N.A. is guaranteed by some of
PAREXELs U.S. entities.
As of September 30, 2006, the Company had approximately $3.9 million in purchase obligations with
various vendors for the purchase of computer software and recruiting services.
OFF-BALANCE SHEET ARRANGEMENTS
The Company has no off-balance sheet arrangements that have or are reasonably likely to have a
current or future effect on the Companys financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that is material to the Companys investors.
FOREIGN CURRENCY EXCHANGE RATES
The Company derived approximately 64.2% of its consolidated service revenue for the three-month
period ended September 30, 2006 from operations outside of the U.S., of which 16.0% was denominated
in British pounds and approximately 36.3% was denominated in Euros. The Company derived
approximately 63.5% of its consolidated service revenue for the three months ended September 30,
2005 from operations outside of the U.S., of which 18.4% was denominated in British pounds and
approximately 35.5% was denominated in Euros. The Company does not have significant operations in
countries in which the economy is considered to be highly inflationary. The Companys financial
statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between foreign
currencies and the U.S. dollar will affect the translation of financial results into U.S. dollars
for purposes of reporting the Companys consolidated financial results.
The Company may be subjected to foreign currency transaction risk when the Companys foreign
subsidiaries enter into contracts or incur liabilities denominated in a currency other than the
foreign subsidiarys functional (local) currency. To the extent the Company is unable to shift the
effects of foreign currency fluctuations to its clients, foreign exchange fluctuations as a result
of currency exchange losses could have a material effect on the
Companys results of operations. The Company has a derivative hedging policy to hedge certain
foreign denominated accounts receivable and intercompany payables. Under this policy, derivatives
are accounted for in accordance with SFAS
16
No. 133 Accounting for Derivative Instruments and Hedging Activities (SFAS 133). The notional
contract amount of these outstanding foreign currency exchange contracts totaled approximately
$13.2 million at September 30, 2006.
Occasionally, the Company enters into other foreign currency exchange contracts to offset the
impact of currency fluctuations. These foreign currency exchange contracts are entered into as
economic hedges, but are not designated as hedges for accounting purposes as defined under SFAS
133. The notional contract amount of these outstanding foreign currency exchange contracts was
approximately $20.1 million at September 30, 2006. The Company does not expect gains or losses on
these contracts to have a material impact on its financial results. During the three-month period
ended September 30, 2006, the Company recorded foreign exchange losses of $0.4 million and during
the three-month period ended September 30, 2005, the Company recorded foreign-exchange gains of
$0.5 million. The Company acknowledges its exposure to additional foreign exchange risk as it
relates to assets and liabilities that are not part of the economic hedge program, but
quantification of this risk is very difficult to assess at any given point in time.
INFLATION
The Company believes the effects of inflation generally do not have a material adverse impact on
its operations or financial condition.
RECENTLY ISSUED ACCOUNTING STANDARDS
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. FAS 157 provides
guidance for using fair value to measure assets and liabilities. The standard also responds to
investors requests for more information about (1) the extent to which companies measure assets and
liabilities at fair value, (2) the information used to measure fair value, and (3) the effect that
fair-value measurements have on earnings. FAS 157 will apply whenever another standard requires
(or permits) assets or liabilities to be measured at fair value. The standard does not expand the
use of fair value to any new circumstances. FAS 157 is effective for financial statements issued
for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years
and will be in effect for PAREXEL beginning on July 1, 2008. The Company is currently evaluating
the potential impact that the adoption of FAS 157 will have on its financial statements.
In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income
Taxes. FIN 48 clarifies the accounting for uncertain income tax positions that are recognized in
a companys financial statements in accordance with the provisions of FASB Statement No. 109,
Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute
for the financial statement recognition and measurement of a tax position taken or expected to be
taken in a tax return. FIN 48 also provides guidance on the derecognition of uncertain positions,
financial statement classification, accounting for interest and penalties, accounting for interim
periods and new disclosure requirements. FIN 48 is effective for fiscal years beginning after
December 15, 2006 and will be in effect for PAREXEL beginning on July 1, 2007. The Company is
currently evaluating the potential impact that the adoption of FIN 48 will have on its financial
statements.
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, which
changes the requirements for the accounting and reporting of a change in accounting principle. FAS
154 applies to all voluntary changes in accounting principle as well as to changes required by an
accounting pronouncement that does not include specific transition provisions. FAS 154 requires
that changes in accounting principle be retrospectively applied. FAS 154 is effective for
accounting changes and corrections of errors made in fiscal years beginning after December 15,
2005. PAREXEL adopted FAS 154 on July 1, 2006 and the adoption of this statement did not have a
material impact on the Companys financial statements in the
first quarter of fiscal year 2007.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
MARKET RISK
Market risk is the potential loss arising from adverse changes in market rates and prices,
such as foreign currency rates, interest rates, and other relevant market rates or price changes.
In the ordinary course of business, the Company is exposed to market risk resulting from changes in
foreign currency exchange rates, and the Company regularly evaluates its exposure to such changes.
The Companys overall risk management strategy seeks to balance the magnitude of the exposure and
the costs and availability of appropriate financial instruments.
17
FOREIGN CURRENCY EXCHANGE RATES
The Company derived approximately 64.2% of its consolidated service revenue for the
three-month period ended September 30, 2006 from operations outside of the U.S., of which 16.0% was
denominated in British pounds and approximately 36.3% was denominated in Euros. The Company
derived approximately 63.5% of its consolidated service revenue for the three months ended
September 30, 2005 from operations outside of the U.S., of which 18.4% was denominated in British
pounds and approximately 35.5% was denominated in Euros. The Company does not have significant
operations in countries in which the economy is considered to be highly inflationary. The Companys
financial statements are denominated in U.S. dollars. Accordingly, changes in exchange rates
between foreign currencies and the U.S. dollar will affect the translation of financial results
into U.S. dollars for purposes of reporting the Companys consolidated financial results.
The Company may be subjected to foreign currency transaction risk when the Companys foreign
subsidiaries enter into contracts or incur liabilities denominated in a currency other than the
foreign subsidiarys functional (local) currency. To the extent the Company is unable to shift the
effects of currency fluctuations to its clients, foreign exchange fluctuations as a result of
currency exchange losses could have a material effect on the Companys results of operations. The
Company has a derivative hedging policy to hedge certain foreign denominated accounts receivable
and intercompany payables. Under this policy, derivatives are accounted for in accordance with
SFAS 133. The notional contract amount of these outstanding foreign currency exchange contracts
totaled approximately $13.2 million at September 30, 2006.
Occasionally, the Company enters into other foreign currency exchange contracts to offset the
impact of currency fluctuations. These foreign currency exchange contracts are entered into as
economic hedges, but are not designated as hedges for accounting purposes as defined under SFAS
133. The notional contract amount of these outstanding foreign currency exchange contracts was
approximately $20.1 million at September 30, 2006. The Company does not expect gains or losses on
these contracts to have a material impact on its financial results. The potential change in the
fair value of these foreign currency exchange contracts that would result from a hypothetical
change of 10% in exchange rates would be approximately $2.0 million. During the three-month period
ended September 30, 2006, the Company recorded foreign exchange loss of $0.4 million and during the
three-month period ended September 30, 2005, the Company recorded foreign exchange gain of $0.5
million, respectively. The Company acknowledges its exposure to additional foreign exchange risk
as it relates to assets and liabilities that are not part of the economic hedge program, but
quantification of this risk is very difficult to assess at any given point in time.
INTEREST RATE
The Companys exposure to interest rate changes is currently minimal as the level of long-term debt
and marketable securities the Company has are minimal. Long-term debt was approximately $0.6
million at September 30, 2006 and approximately $0.7 million at June 30, 2006. Marketable
securities were zero at September 30, 2006 and $10.0 million at June 30, 2006.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
The Companys management, with the participation of the Companys chief executive officer and chief
financial officer, evaluated the effectiveness of the Companys disclosure controls and procedures
as of September 30, 2006. The term disclosure controls and procedures, as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company
that are designed to ensure that information required to be disclosed by a company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the SECs rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by a company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the companys management, including its principal executive and
principal financial officers, as appropriate to allow timely decisions regarding required
disclosure. Management recognizes that any controls and procedures, no matter how well designed
and operated, can provide only reasonable assurance of achieving their objectives and management
necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls
and procedures. Based on the evaluation of the Companys disclosure controls and procedures as of
September 30, 2006, the Companys chief executive officer and chief financial officer concluded
that, as of such date, the Companys disclosure controls and procedures were effective at the
reasonable assurance level.
18
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
No change in the Companys internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended September
30, 2006 that has materially affected, or is reasonably likely to materially affect, the Companys
internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1A. RISK FACTORS
In addition to other information in this report, the following risk factors should be
considered carefully in evaluating our Company and our business. These risk factors could cause
actual results to differ from those indicated by forward-looking statements made in this report,
including in the section of this report entitled Managements Discussion and Analysis of Financial
Condition and Results of Operations and other forward-looking statements that we may make from
time to time. If any of the following risks occur, our business, financial condition, or results
of operations would likely suffer.
THE LOSS, MODIFICATION, OR DELAY OF LARGE OR MULTIPLE CONTRACTS MAY NEGATIVELY IMPACT OUR
FINANCIAL PERFORMANCE
Our clients generally can terminate their contracts with us upon 30 to 60 days notice or can
delay the execution of services. The loss or delay of a large contract or the loss or delay of
multiple contracts could adversely affect our operating results, possibly materially. We have in
the past experienced contract cancellations, which have adversely affected our operating results,
including a major Phase III cancellation during the first quarter of fiscal year 2005.
Clients terminate or delay their contracts for a variety of reasons, including,:
|
|
|
merger or potential merger related activities; |
|
|
|
|
failure of products being tested to satisfy safety requirements; |
|
|
|
|
failure of products being tested to prove effective; |
|
|
|
|
products having unexpected or undesired clinical results; |
|
|
|
|
client decisions to forego a particular study, perhaps for economic reasons; |
|
|
|
|
insufficient patient enrollment in a study; |
|
|
|
|
insufficient investigator recruitment; |
|
|
|
|
production problems which cause shortages of the product; |
|
|
|
|
product withdrawal following market launch; and |
|
|
|
|
shut down of manufacturing facilities. |
In addition, clients may determine to proceed with fewer clinical trials or conduct them without
the assistance of bio/pharmaceutical services companies if they are trying to reduce costs as a
result of budgetary limits or changing priorities. These factors may cause such clients to cancel
contracts with us.
WE FACE INTENSE COMPETITION IN MANY AREAS OF OUR BUSINESS; IF WE DO NOT COMPETE EFFECTIVELY, OUR
BUSINESS WILL BE HARMED
The bio/pharmaceutical services industry is highly competitive and we face numerous competitors in
many areas of our business. If we fail to compete effectively, we may lose clients, which would
cause our business to suffer.
19
We primarily compete against in-house departments of pharmaceutical companies, other full service
clinical research organizations, or CROs, small specialty CROs, and to a lesser extent,
universities, teaching hospitals, and other site organizations. Some of the larger CROs against
which we compete include Quintiles Transnational Corporation, Covance, Inc. and Pharmaceutical
Product Development Inc. In addition, our PCMS business competes with a large and fragmented group
of specialty service providers, including advertising/promotional companies, major consulting firms
with pharmaceutical industry groups and smaller companies with pharmaceutical industry focus.
Perceptive competes primarily with CROs, information technology companies and other software
companies. Some of these competitors, including the in-house departments of pharmaceutical
companies, have greater capital, technical and other resources than us. In addition, our
competitors that are smaller specialized companies may compete effectively against us because of
their concentrated size and focus.
THE FIXED RATE NATURE OF OUR CONTRACTS COULD HURT OUR OPERATING RESULTS
Approximately 90% of our contracts are fixed rate. If we fail to adequately price our
contracts or if we experience significant cost overruns, our gross margins on the contracts would
be reduced and we could lose money on contracts. In the past, we have had to commit unanticipated
resources to complete projects, resulting in lower gross margins on those projects. We might
experience similar situations in the future.
IF GOVERNMENTAL REGULATION OF THE DRUG, MEDICAL DEVICE AND BIOTECHNOLOGY INDUSTRY CHANGES, THE NEED
FOR OUR SERVICES COULD DECREASE
Governmental regulation of the drug, medical device and biotechnology product development process
is complicated, extensive, and demanding. A large part of our business involves assisting
pharmaceutical and biotechnology companies through the regulatory approval process. Changes in
regulations, that, for example, streamline procedures or relax approval standards, could eliminate
or reduce the need for our services. If companies regulated by the Food and Drug Administration
(FDA) or similar foreign regulatory authorities needed fewer of our services, we would have fewer
business opportunities and our revenues would decrease, possibly materially.
In the U.S., the FDA and the Congress have attempted to streamline the regulatory process by
providing for industry user fees that fund the hiring of additional reviewers and better management
of the regulatory review process. In Europe, governmental authorities have approved common
standards for clinical testing of new drugs throughout the European Union by adopting standards for
good clinical practice (GCP) and by making the clinical trial application and approval process
more uniform across member states. The FDA has had GCP in place as a regulatory standard and
requirement for new drug approval for many years and Japan adopted GCP in 1998. The U.S., Europe
and Japan have also collaborated in the 15-year-long International Conference on Harmonisation, or
ICH, the purpose of which is to eliminate duplicative or conflicting regulations in the three
regions. The ICH partners have agreed upon a common format (the Common Technical Document) for new
drug marketing applications that reduces the need to tailor the format to each region. Such
efforts and similar efforts in the future that streamline the regulatory process may reduce the
demand for our services.
Parts of our PCMS business advises clients on how to satisfy regulatory standards for manufacturing
and clinical processes and on other matters related to the enforcement of government regulations by
the FDA and other regulatory bodies. Any reduction in levels of review of manufacturing or
clinical processes or levels of regulatory enforcement, generally, would result in fewer business
opportunities for our business in this area.
IF WE FAIL TO COMPLY WITH EXISTING REGULATIONS, OUR REPUTATION AND OPERATING RESULTS WOULD BE
HARMED
Our business is subject to numerous governmental regulations, primarily relating to worldwide
pharmaceutical product development and regulatory approval and the conduct of clinical trials. If
we fail to comply with these governmental regulations, it could result in the termination of our
ongoing research, development or sales and marketing projects, or the disqualification of data for
submission to regulatory authorities. We also could be barred from providing clinical trial
services in the future or could be subjected to fines. Any of these consequences would harm our
reputation, our prospects for future work and our operating results. In addition, we may have to
repeat research or redo trials. If we are required to repeat research or redo trials, we may be
contractually required to do so at no further cost to our clients, but at substantial cost to us.
20
WE MAY LOSE BUSINESS OPPORTUNITIES AS A RESULT OF HEALTH CARE REFORM AND THE EXPANSION OF
MANAGED-CARE ORGANIZATIONS
Numerous governments, including the U.S. government and governments outside of the U.S. have
undertaken efforts to control growing health care costs through legislation, regulation and
voluntary agreements with medical care providers and drug companies. If these efforts are
successful, drug, medical device and biotechnology companies may react by spending less on research
and development. If this were to occur, we would have fewer business opportunities and our
revenues could decrease, possibly materially. In addition, new laws or regulations may create a
risk of liability, increase our costs or limit our service offerings.
For instance, in the past the U.S. Congress has entertained several comprehensive health care
reform proposals. The proposals were generally intended to expand health care coverage for the
uninsured and reduce the growth of total health care expenditures. While the U.S. Congress has not
yet adopted any comprehensive reform proposals, members of Congress may raise similar proposals in
the future. We are unable to predict the likelihood that health care reform proposals will be
enacted into law.
In addition to health care reform proposals, the expansion of managed-care organizations in the
health care market and managed-care organizations efforts to cut costs by limiting expenditures on
pharmaceuticals and medical devices could result in pharmaceutical, biotechnology and medical
device companies spending less on research and development. If this were to occur, we would have
fewer business opportunities and our revenues could decrease, possibly materially.
IF WE DO NOT KEEP PACE WITH RAPID TECHNOLOGICAL CHANGES, OUR PRODUCTS AND SERVICES MAY BECOME
LESS COMPETITIVE OR OBSOLETE, ESPECIALLY IN OUR PERCEPTIVE BUSINESS
The biotechnology, pharmaceutical and medical device industries generally, and clinical
research specifically, are subject to increasingly rapid technological changes. Our competitors or
others might develop technologies, products or services that are more effective or commercially
attractive than our current or future technologies, products or services, or render our
technologies, products or services less competitive or obsolete. If competitors introduce superior
technologies, products or services and we cannot make enhancements to our technologies, products
and services necessary to remain competitive, our competitive position would be harmed. If we are
unable to compete successfully, we may lose clients or be unable to attract new clients, which
could lead to a decrease in our revenue.
BECAUSE WE DEPEND ON A SMALL NUMBER OF INDUSTRIES AND CLIENTS FOR ALL OF OUR BUSINESS, THE LOSS
OF BUSINESS FROM A SIGNIFICANT CLIENT COULD HARM OUR BUSINESS, REVENUE AND FINANCIAL CONDITION
The loss of, or a material reduction in the business of, a significant client could cause a
substantial decrease in our revenue and adversely affect our business and financial condition,
possibly materially. In both fiscal year 2006 and fiscal year 2005, our five largest clients
accounted for approximately 25% of our consolidated service revenue and no single client accounted
for 10% or more of consolidated service revenue. We expect that a small number of clients will
continue to represent a significant part of our consolidated revenue. Our contracts with these
clients generally can be terminated on short notice. We have in the past experienced contract
cancellations with significant clients.
IF OUR PERCEPTIVE BUSINESS IS UNABLE TO MAINTAIN CONTINUOUS, EFFECTIVE, RELIABLE AND SECURE
OPERATION OF ITS COMPUTER HARDWARE, SOFTWARE AND INTERNET APPLICATIONS AND RELATED TOOLS AND
FUNCTIONS, ITS BUSINESS WILL BE HARMED
Our Perceptive Informatics business involves collecting, managing, manipulating and analyzing
large amounts of data, and communicating data via the Internet. In our Perceptive Informatics
business, we depend on the continuous, effective, reliable and secure operation of computer
hardware, software, networks, telecommunication networks, Internet servers and related
infrastructure. If the hardware or software malfunctions or access to data by internal research
personnel or customers through the Internet is interrupted, our Perceptive Informatics business
could suffer. In addition, any sustained disruption in Internet access provided by third parties
could adversely impact our Perceptive Informatics business.
21
Although the computer and communications hardware used in our Perceptive Informatics business
is protected through physical and software safeguards, it is still vulnerable to fire, storm,
flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, and
similar events. In addition, the Perceptive Informatics software products are complex and
sophisticated, and could contain data, design or software errors that could be difficult to detect
and correct. If Perceptive fails to maintain and further develop the necessary computer capacity
and data to support the needs of our Perceptive Informatics customers, it could result in a loss of
or a delay in revenue and market acceptance.
IF WE ARE UNABLE TO ATTRACT SUITABLE WILLING VOLUNTEERS FOR THE CLINICAL TRIALS OF OUR CLIENTS, OUR
CRS BUSINESS MAY SUFFER
One of the factors on which our CRS business competes is the ability to recruit patients for the
clinical studies we are managing. These clinical trials rely upon the ready accessibility and
willing participation of volunteer subjects. These subjects generally include volunteers from the
communities in which the studies are conducted. Although to date these communities have provided a
substantial pool of potential subjects for research studies, there may not be enough patients
available with the traits necessary to conduct the studies. For example, if we manage a study for
a treatment of a particular type of cancer, our ability to conduct the study may be limited by the
number of patients that we can recruit that have that form of cancer. If multiple organizations
are conducting similar studies and competing for patients, it could also make our recruitment
efforts more difficult. If we were unable to attract suitable and willing volunteers on a
consistent basis, it would have an adverse effect on the trials being managed by our CRS business,
which could have a material adverse effect on our CRS business.
IF WE CANNOT RETAIN OUR HIGHLY QUALIFIED MANAGEMENT AND TECHNICAL PERSONNEL, OUR BUSINESS
WOULD BE HARMED
We rely on the expertise of our Chairman and Chief Executive Officer, Josef H. von Rickenbach and
it would be difficult and expensive to find a qualified replacement with the level of specialized
knowledge of our products and services and the bio/pharmaceutical services industry. We are a
party to an employment agreement with Mr. von Rickenbach, which may be terminated by us or Mr. von
Rickenbach upon notice to the other party.
In addition, in order to compete effectively, we must attract and maintain qualified sales,
professional, scientific, and technical operating personnel. Competition for these skilled
personnel, particularly those with a medical degree, a Ph.D. or equivalent degrees, is intense. We
may not be successful in attracting or retaining key personnel.
WE MAY HAVE SUBSTANTIAL EXPOSURE TO PAYMENT OF PERSONAL INJURY CLAIMS AND MAY NOT HAVE ADEQUATE
INSURANCE TO COVER SUCH CLAIMS
Our CRS business primarily involves the testing of experimental drugs and medical devices on
consenting human volunteers pursuant to a study protocol. Clinical research involves a risk of
liability for personal injury or death to patients who participate in the study or who use a
product approved by regulatory authorities after the clinical research has concluded, due to, among
other reasons, possible unforeseen adverse side effects or improper administration of the drug or
device by physicians. In some cases, these patients are already seriously ill and are at risk of
further illness or death.
In order to mitigate the risk of liability, we seek to include indemnity provisions in our Clinical
Research Services contracts with clients and with investigators. However, we are not able to
include indemnity provisions in all of our contracts. The indemnity provisions we include in these
contracts would not cover our exposure if:
|
|
|
we had to pay damages or incur defense costs in connection with a claim that is
outside the scope of an indemnity; or |
|
|
|
|
a client failed to indemnify us in accordance with the terms of an indemnity
agreement because it did not have the financial ability to fulfill its indemnification
obligation or for any other reason. |
We also carry insurance to cover our risk of liability. However, our insurance is subject to
deductibles and coverage limits and may not be adequate to cover claims. In addition, liability
coverage is expensive. In the future, we may not be able to maintain or obtain liability insurance
on reasonable terms, at a reasonable cost, or in sufficient amounts to protect us against losses
due to claims.
22
In March 2006, we conducted a Phase I clinical trial on behalf of TeGenero AG, a German
pharmaceutical company. During the trial, six participants experienced adverse reactions to the
TeGenero compound being tested. Through September 30, 2006, we
recorded approximately $1.4 million in
legal fees and other incremental costs in connection with the incident. To date, none of the
participants in the clinical trial have filed suit against us. We carry insurance to cover risks
such as this, but our insurance is subject to deductibles and coverage limits and may not be
adequate to cover claims against us. While we believe that TeGenero is responsible to indemnify us
with respect to claims related to this matter, TeGenero filed for insolvency in July 2006, which
likely will limit any recovery by us from them. In addition, while TeGenero carried insurance with
respect to this type of matter, this insurance also is subject to deductibles and coverage limits.
OUR BUSINESS IS SUBJECT TO INTERNATIONAL ECONOMIC, POLITICAL, AND OTHER RISKS THAT COULD NEGATIVELY
AFFECT OUR RESULTS OF OPERATIONS OR FINANCIAL POSITION
We provide most of our services on a worldwide basis. Our service revenue from non-U.S. operations
represented approximately 64.2% of total consolidated service revenue for the three months ended
September 30, 2006 and approximately 63.5% of total consolidated service revenue for the three
months ended September 30, 2005. More specifically, our service revenue from operations in the
United Kingdom represented 16.0% of total consolidated service revenue for the three months ended
September 30, 2006 and 18.4% of total consolidated service revenue for the three months ended
September 30, 2005. Our service revenue from operations in Germany represented 19.3% of total
consolidated service revenue for the three months ended September 30, 2006 and 18.8% of total
consolidated service revenue for the three months ended September 30, 2005. Accordingly, our
business is subject to risks associated with doing business internationally, including:
|
|
|
changes in a specific countrys or regions political or economic conditions,
including Western Europe, in particular; |
|
|
|
|
potential negative consequences from changes in tax laws affecting our ability to repatriate profits; |
|
|
|
|
difficulty in staffing and managing widespread operations; |
|
|
|
|
unfavorable labor regulations applicable to its European or other international operations; |
|
|
|
|
changes in foreign currency exchange rates; and |
|
|
|
|
longer payment cycles of foreign customers and difficulty of collecting receivables
in foreign jurisdictions. |
OUR OPERATING RESULTS HAVE FLUCTUATED BETWEEN QUARTERS AND YEARS AND MAY CONTINUE TO FLUCTUATE IN
THE FUTURE, WHICH COULD AFFECT THE PRICE OF OUR COMMON STOCK
Our quarterly and annual operating results have varied and will continue to vary in the future as a
result of a variety of factors. For example, our income from operations totaled $10.6 million for
the fiscal quarter ended December 31, 2005, $11.2 million for the fiscal quarter ended March 31,
2006, $13.1 million for the fiscal quarter ended June 30, 2006 and $11.3 million for the fiscal
quarter ended September 30, 2006. Factors that cause these variations include:
|
|
|
the level of new business authorizations in a particular quarter or year; |
|
|
|
|
the timing of the initiation, progress, or cancellation of significant projects; |
|
|
|
|
exchange rate fluctuations between quarters or years; |
|
|
|
|
restructuring charges; |
|
|
|
|
the mix of services offered in a particular quarter or year; |
|
|
|
|
the timing of the opening of new offices; |
|
|
|
|
costs and the related financial impact of acquisitions; |
|
|
|
|
the timing of internal expansion; |
23
|
|
|
the timing and amount of costs associated with integrating acquisitions; |
|
|
|
|
the timing and amount of startup costs incurred in connection with the introduction
of new products, services or subsidiaries; and |
|
|
|
|
the dollar amount of changes in contract scope finalized during a particular period. |
Many of these factors, such as the timing of cancellations of significant projects and exchange
rate fluctuations between quarters or years, are beyond our control.
Approximately 60-65% of our operating costs are fixed in the short term with a significant portion
of those costs related to personnel. Total personnel costs are estimated to have accounted for
approximately 80% of our total operating costs in fiscal year 2006. As a result, the effect on our
revenues of the timing of the completion, delay or loss of contracts, or the progress of client
projects, could cause our operating results to vary substantially between reporting periods.
If our operating results do not match the expectations of securities analysts and investors, the
trading price of our common stock will likely decrease.
OUR REVENUE AND EARNINGS ARE EXPOSED TO EXCHANGE RATE FLUCTUATIONS
Approximately 64.2% of our total consolidated service revenue for the three months ended September
30, 2006 and approximately 63.5% of our total consolidated service revenue for the three months
ended September 30, 2005 were from non-U.S. operations. Our financial statements are denominated
in U.S. dollars. As a result, changes in foreign currency exchange rates could have and have had a
significant effect on our operating results. For example, as a result of year-over-year foreign
currency fluctuation, service revenue for the three months ended September 30, 2006 was positively
impacted by approximately $2.4 million as compared to the three months ended September 30, 2005.
Exchange rate fluctuations between local currencies and the U.S. dollar create risk in several
ways, including:
|
|
|
Foreign Currency Translation Risk. The revenue and expenses of our foreign operations
are generally denominated in local currencies, primarily the British pound and the Euro,
and then are translated into U.S. dollars for financial reporting purposes. For the three
months ended September 30, 2006, 16.0% of total consolidated service revenue was
denominated in British pounds and approximately 36.3% of total consolidated service revenue
was denominated in Euros. For the three months ended September 30, 2005, 18.4% of total
consolidated service revenue was denominated in British pounds and approximately 35.5% of
total consolidated service revenue was denominated in Euros. Accordingly, changes in
exchange rates between foreign currencies and the U.S. dollar will affect the translation
of foreign results into U.S. dollars for purposes of reporting our consolidated results. |
|
|
|
|
Foreign Currency Transaction Risk. We may be subjected to foreign currency transaction
risk when our foreign subsidiaries enter into contracts or incur liabilities denominated in
a currency other than the foreign subsidiaries functional (local) currency. To the extent
we are unable to shift the effects of currency fluctuations to the clients, foreign
exchange fluctuations as a result of foreign currency exchange losses could have a material
adverse effect on our results of operations. |
Although we try to limit these risks through exchange rate fluctuation provisions stated in our
service contracts, or by hedging transaction risk with foreign currency exchange contracts, we may
still experience fluctuations in financial results from our operations outside of the U.S., and may
not be able to favorably reduce the currency transaction risk associated with our service
contracts.
OUR BUSINESS HAS EXPERIENCED SUBSTANTIAL EXPANSION IN THE PAST AND SUCH EXPANSION AND ANY FUTURE
EXPANSION COULD STRAIN OUR RESOURCES IF NOT PROPERLY MANAGED
We have expanded our business substantially in the past. Future rapid expansion could strain our
operational, human and financial resources. In order to manage expansion, we must:
|
|
|
continue to improve operating, administrative, and information systems; |
|
|
|
|
accurately predict future personnel and resource needs to meet client contract commitments; |
24
|
|
|
track the progress of ongoing client projects; and |
|
|
|
|
attract and retain qualified management, sales, professional, scientific and
technical operating personnel. |
If we do not take these actions and are not able to manage the expanded business, the expanded
business may be less successful than anticipated, and we may be required to allocate additional
resources to the expanded business, which we would have otherwise allocated to another part of our
business.
We may face additional risks in expanding our foreign operations. Specifically, we may find it
difficult to:
|
|
|
assimilate differences in foreign business practices, exchange rates and regulatory requirements; |
|
|
|
|
operate amid political and economic instability; |
|
|
|
|
hire and retain qualified personnel; and |
|
|
|
|
overcome language, tariff and other barriers. |
WE MAY MAKE ACQUISITIONS IN THE FUTURE, WHICH MAY LEAD TO DISRUPTIONS TO OUR ONGOING BUSINESS
We have made a number of acquisitions and will continue to review new acquisition opportunities.
If we are unable to successfully integrate an acquired company, the acquisition could lead to
disruptions to our business. The success of an acquisition will depend upon, among other things,
our ability to:
|
|
|
assimilate the operations and services or products of the acquired company; |
|
|
|
|
integrate acquired personnel; |
|
|
|
|
retain and motivate key employees; |
|
|
|
|
retain customers; |
|
|
|
|
identify and manage risks facing the acquired company; and |
|
|
|
|
minimize the diversion of managements attention from other business concerns. |
Acquisitions of foreign companies may also involve additional risks, including assimilating
differences in foreign business practices and overcoming language and cultural barriers.
In the event that the operations of an acquired business do not meet our performance expectations,
we may have to restructure the acquired business or write-off the value of some or all of the
assets of the acquired business.
OUR EFFECTIVE INCOME TAX RATE MAY FLUCTUATE FROM QUARTER-TO-QUARTER, WHICH MAY AFFECT EARNINGS AND
EARNINGS PER SHARE
Our quarterly effective income tax rate is influenced by our projected profitability in the various
taxing jurisdictions in which we operate. Changes in the distribution of profits and losses among
taxing jurisdictions may have a significant impact on our effective income tax rate, which in turn
could have a material adverse effect on our net income and earnings per share. Factors that affect
the effective income tax rate include, but are not limited to:
|
|
|
the requirement to exclude from our quarterly worldwide effective income tax
calculations losses in jurisdictions where no tax benefit can be recognized; |
|
|
|
|
actual and projected full year pretax income; |
|
|
|
|
changes in tax laws in the various taxing jurisdictions; |
|
|
|
|
audits by the taxing authorities; and
|
25
|
|
|
the establishment of valuation allowances against deferred tax assets if it is
determined that it is more likely than not that future tax benefits will not be realized. |
Fluctuations in our effective income tax rate could cause fluctuations in our earnings and earnings
per share, which can affect our stock price.
OUR CORPORATE GOVERNANCE STRUCTURE, INCLUDING PROVISIONS OF OUR ARTICLES OF ORGANIZATION, AND
BY-LAWS, AND OUR SHAREHOLDER RIGHTS PLAN, AND MASSACHUSETTS LAW MAY DELAY OR PREVENT A CHANGE IN
CONTROL OR MANAGEMENT THAT STOCKHOLDERS MAY CONSIDER DESIRABLE
Provisions of our articles of organization, by-laws and our shareholder rights plan, as well as
provisions of Massachusetts law, may enable our management to resist acquisition of us by a third
party, or may discourage a third party from acquiring us. These provisions include the following:
|
|
|
we have divided our board of directors into three classes that serve staggered
three-year terms; |
|
|
|
|
we are subject to Section 8.06 of the Massachusetts Business Corporation Law which
provides that directors may only be removed by stockholders for cause, vacancies in our
board of directors may only be filled by a vote of our board of directors and the number
of directors may be fixed only by our board of directors; |
|
|
|
|
we are subject to Chapter 110F of the Massachusetts General Laws which limits our
ability to engage in business combinations with certain interested stockholders; |
|
|
|
|
our stockholders are limited in their ability to call or introduce proposals at
stockholder meetings; and |
|
|
|
|
our shareholder rights plan would cause a proposed acquirer of 20% or more of our
outstanding shares of common stock to suffer significant dilution. |
These provisions could have the effect of delaying, deferring, or preventing a change in control of
us or a change in our management that stockholders may consider favorable or beneficial. These
provisions could also discourage proxy contests and make it more difficult for stockholders to
elect directors and take other corporate actions. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our stock.
In addition, our board of directors may issue preferred stock in the future without stockholder
approval. If our board of directors issues preferred stock, the holders of common stock would be
subordinate to the rights of the holders of preferred stock. Our board of directors ability to
issue the preferred stock could make it more difficult for a third party to acquire, or discourage
a third party from acquiring, a majority of our stock.
OUR STOCK PRICE HAS BEEN AND MAY IN THE FUTURE BE VOLATILE, WHICH COULD LEAD TO LOSSES BY INVESTORS
The market price of our common stock has fluctuated widely in the past and may continue to do so in
the future. On November 6, 2006, the closing sale price of our common stock on the NASDAQ Global
Select Market was $31.29 per share. During the period from October 1, 2004 to September 30, 2006,
the closing price of our common stock ranged from a high of $37.28 per share to a low of $17.28 per
share. Investors in our common stock must be willing to bear the risk of such fluctuations in
stock price and the risk that the value of an investment in our stock could decline.
Our stock price can be affected by quarter-to-quarter variations in a number of factors including,
but not limited to:
|
|
|
operating results; |
|
|
|
|
earnings estimates by analysts; |
|
|
|
|
market conditions in the industry; |
|
|
|
|
prospects of health care reform; |
|
|
|
|
changes in government regulations;
|
26
|
|
|
general economic conditions, and |
|
|
|
|
our effective income tax rate. |
In addition, the stock market has from time to time experienced significant price and volume
fluctuations that are not related to the operating performance of particular companies. These
market fluctuations may adversely affect the market price of our common stock. Since our common
stock has traded in the past at a relatively high price-earnings multiple, due in part to analysts
expectations of earnings growth, the price of the stock could quickly and substantially decline as
a result of even a relatively small shortfall in earnings from, or a change in, analysts
expectations.
ITEM 6. EXHIBITS
|
|
See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits
filed as part of this quarterly report, which Exhibit Index is incorporated by this reference. |
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
PAREXEL International Corporation
|
|
Date: November 9, 2006 |
By: |
/s/ Josef H. von Rickenbach
|
|
|
|
Josef H. von Rickenbach |
|
|
|
Chairman of the Board and Chief Executive
Officer |
|
|
|
|
|
|
|
|
|
|
Date: November 9, 2006 |
By: |
/s/ James F. Winschel, Jr.
|
|
|
|
James F. Winschel, Jr. |
|
|
|
Senior Vice President and Chief Financial
Officer |
|
|
28
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
31.1
|
|
Principal executive officer certification pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002 |
|
|
|
31.2
|
|
Principal financial officer certification pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002 |
|
|
|
32.1
|
|
Principal executive officer certification pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 |
|
|
|
32.2
|
|
Principal financial officer certification pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 |
29